TCM
TRDA icon

TCG Crossover Management’s Entrada Therapeutics TRDA Stock Holding History

TCG Crossover Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.8M Sell
1,060,230
-1,227,270
-54% -$11.8M 0.19% 46
2026
Q1 		$28.9M Buy
2,287,500
+199,108
+10% +$2.28M 0.83% 30
2025
Q4 		$21.5M Buy
2,088,392
+1,503,437
+257% +$12.7M 0.71% 30
2025
Q3 		$3.39M Hold
584,955
– – 0.17% 39
2025
Q2 		$3.93M Hold
584,955
– – 0.45% 32
2025
Q1 		$5.29M Hold
584,955
– – 0.72% 31
2024
Q4 		$10.1M Hold
584,955
– – 0.99% 30
2024
Q3 		$9.35M Hold
584,955
– – 0.79% 26
2024
Q2 		$8.34M Hold
584,955
– – 0.87% 24
2024
Q1 		$8.29M Hold
584,955
– – 0.66% 28
2023
Q4 		$8.83M Hold
584,955
– – 0.98% 24
2023
Q3 		$9.24M Hold
584,955
– – 1.36% 22
2023
Q2 		$8.86M Hold
584,955
– – 1.45% 17
2023
Q1 		$8.48M Hold
584,955
– – 1.65% 16
2022
Q4 		$7.91M Sell
584,955
-57,234
-9% -$1M 1.4% 17
2022
Q3 		$10.1M Sell
642,189
-21,505
-3% -$273K 3.04% 10
2022
Q2 		$8.08M Hold
663,694
– – 3.43% 10
2022
Q1 		$6.13M Hold
663,694
– – 2.46% 16
2021
Q4 		$11.4M Buy
+663,694
New +$16.1M 5.32% 9

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCG Crossover Management's TRDA Position: Q2 2026 in Review

TCG Crossover Management reduced its Entrada Therapeutics (TRDA) stake by 54% in Q2 2026, selling an estimated $11.8M and leaving 1,060,230 shares worth $7.8M. The position accounts for 0.19% of the portfolio, ranked #46.

TCG Crossover Management first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $28.9M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • TCG Crossover Management held 1,060,230 shares of Entrada Therapeutics worth $7.8M as of Q2 2026.
  • TCG Crossover Management sold 1,227,270 Entrada Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Entrada Therapeutics made up 0.19% of TCG Crossover Management's portfolio in Q2 2026, its #46 holding.
  • TCG Crossover Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • TCG Crossover Management's Entrada Therapeutics position peaked at $28.9M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.